Pfizer Is Seeking The FDA’s Approval For A RSV Vaccine

If approved, the shot will be the first vaccine to fight RSV.

Pfizer says that it is going to seek the FDA’s approval to create a vaccine for Respiratory Syncytial Virus.

RSV can be a mild illness with cold-like symptoms. However, it can be more serious in cases of older adults and infants. World-wide, the illness causes nearly 33 million infections in children under 5-years-old and hospitalizes 3.6 million yearly.

Pfizer’s vaccine is administered to pregnant women who produce antibodies that can protect the baby after birth.

During the trial, the vaccine was 80% effective at preventing severe RSV disease in infants during the first three months of life.

If the FDA approves, the shot will be the first vaccine to fight against the disease and the first new product related to the infection in over two decades.